Advertisement
Advertisement
U.S. markets open in 3 hours 2 minutes
Advertisement
Advertisement
Advertisement
Advertisement

MediWound Ltd. (MDWD)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
1.6000-0.0600 (-3.61%)
At close: 03:59PM EST
Advertisement
Full screen
Loading interactive chart...
  • Zacks

    MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates

    MediWound (MDWD) delivered earnings and revenue surprises of -30% and 24.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update

    $30.5 million in gross proceeds raised; operating cash runway through 2025 NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues Company focused on the billion-dollar market opportunity with EscharEx Phase 3 clinical study to begin in first-half 2023 Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-ge

  • GlobeNewswire

    MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs

    Paper published in the November 2022 issue of Podiatry Management(Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM, MS) YAVNE, Israel, Nov. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the publication of a paper, “Introducing Bromelain-Based Enzymatic Debridement” in the journal Podiatry Management. The paper reviewed

Advertisement
Advertisement